LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3729 | 3643 | 1.0251 | 1.0402 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3769 | 3772 | 0.9993 | 0.9988 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3361 | 3643 | 0.9217 | 0.8759 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3598 | 3772 | 0.9544 | 0.9322 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3633 | 3643 | 0.9986 | 0.9999 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 2992 | 3772 | 0.7934 | 0.6856 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 3228 | 3643 | 0.8877 | 0.8272 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2119 | 3772 | 0.5619 | 0.3061 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1963 | 3643 | 0.5396 | 0.2443 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP5 | 72 | hr | 1476 | 1221 | 3772 | 0.3240 | -0.1307 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP6 | 72 | hr | 1476 | 881 | 3643 | 0.2419 | -0.3288 |
| SK-BR-3 | Tozasertib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 1200 | 3772 | 0.3185 | -0.1419 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 1253 | 3772 | 0.3323 | -0.1142 |
| SK-BR-3 | Tozasertib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1236 | 3772 | 0.3278 | -0.1232 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1303 | 3772 | 0.3456 | -0.0882 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1292 | 3772 | 0.3427 | -0.0937 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 72 | hr | 1476 | 1328 | 3772 | 0.3522 | -0.0755 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3656 | 3643 | 1.0020 | 1.0006 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3841 | 3643 | 1.0535 | 1.0802 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3744 | 3643 | 1.0260 | 1.0366 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 3810 | 3643 | 1.0483 | 1.0778 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 4092 | 3643 | 1.1233 | 1.1875 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 72 | hr | 1476 | 3656 | 3643 | 1.0032 | 1.0045 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3906 | 3643 | 1.0733 | 1.1143 |
| SK-BR-3 | NVP-TAE684 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2822 | 3643 | 0.7747 | 0.6429 |